• 1
    DeLellis RA, LIoyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours: Pathology and genetics of tumours of Endocrine Organs. Lyon: IARC press, 2004.
  • 2
    Cameselle-Teijeiro J, Chan JK. Cribriform-morular variant of papillary carcinoma: a distinctive variant representing the sporadic counterpart of familial adenomatous polyposis-associated thyroid carcinoma? Mod Pathol 1999; 12: 40011.
  • 3
    Gaertner EM, Davidson M, Wenig BM. The columnar cell variant of thyroid papillary carcinoma. Case report and discussion of an unusually aggressive thyroid papillary carcinoma. Am J Surg Pathol 1995; 19: 9407.
  • 4
    Asioli S, Erickson LA, Lloyd RV. Solid cell nests in Hashimoto’s thyroiditis sharing features with papillary thyroid microcarcinoma. Endocr Pathol 2009; 20: 197203.
  • 5
    Carney JA, Hirokawa M, Lloyd RV, Papotti M, Sebo TJ. Hyalinizing trabecular tumors of the thyroid gland are almost all benign. Am J Surg Pathol 2008; 32: 187789.
  • 6
    Hofman V, Lassalle S, Bonnetaud C et al. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch 2009; 455: 2133.
  • 7
    Elsheikh TM, Asa SL, Chan JK et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 2008; 130: 73644.
  • 8
    Kakudo K, Bai Y, Katayama S et al. Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute. Pathol Int 2009; 59: 35967.
  • 9
    Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol 2002; 117: 14350.
  • 10
    Serra S, Asa SL. Controversies in thyroid pathology: the diagnosis of follicular neoplasms. Endocr Pathol 2008; 19: 15665.
  • 11
    Hirokawa M, Carney JA, Goellner JR et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 2002; 26: 150814.
  • 12
    Chan JK. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002; 117: 168.
  • 13
    Williams ED. Guest editorial: two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 2000; 8: 1813.
  • 14
    Fusco A, Chiappetta G, Hui P et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol 2002; 160: 215767.
  • 15
    Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 2005; 18: 5416.
  • 16
    Thompson LD, Wieneke JA, Paal E, Frommelt RA, Adair CF, Heffess CS. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001; 91: 50524.
  • 17
    Mai KT, Yazdi HM, Perkins DG, Commons AS, Thomas J. Papillary thyroid carcinoma and related thyroid neoplastic lesions: a light microscopic study with emphasis on nuclear changes. Tumori 2000; 86: 23849.
  • 18
    LiVolsi VA. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003; 98: 1997; author reply.
  • 19
    Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003; 97: 11815.
  • 20
    Jing X, Nakamura Y, Nakamura M et al. Detection of Epstein–Barr virus DNA in gastric carcinoma with lymphoid stroma. Viral Immunol 1997; 10: 4958.
  • 21
    Zuo H, Nakamura Y, Yasuoka H et al. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 2007; 57: 1220.
  • 22
    Kakudo K, Katoh R, Sakamoto A et al. Thyroid gland: international case conference. Endocr Pathol 2002; 13: 1314.
  • 23
    Rosai J. The encapsulated follicular variant of papillary thyroid carcinoma: back to the drawing board. Endocr Pathol 2010; 21: 711.
  • 24
    Lloyd RV, Erickson LA, Casey MB et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004; 28: 133640.
  • 25
    Piana S, Frasoldati A, Di Felice E, Gardini G, Tallini G, Rosai J. Encapsulated well-differentiated follicular-patterned thyroid carcinomas do not play a significant role in the fatality rates from thyroid carcinoma. Am J Surg Pathol 2010; 34: 86872.
  • 26
    Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010; 21: 809.
  • 27
    Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 2006; 17: 22534.
  • 28
    Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol 2006; 19: 16317.
  • 29
    Bukhari U, Sadiq S, Kehar SI. Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma. J Pak Med Assoc 2009; 59: 158.
  • 30
    Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006; 126: 7008.
  • 31
    Fontaine JF, Mirebeau-Prunier D, Franc B et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene 2008; 27: 222836.
  • 32
    Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399404.
  • 33
    Trovisco V, Vieira de Castro I, Soares P et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004; 202: 24751.
  • 34
    Di Cristofaro J, Marcy M, Vasko V et al. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 2006; 37: 82430.
  • 35
    Rivera M, Ricarte-Filho J, Knauf J et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 2010; 23: 1191200.
  • 36
    Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120: 717.
  • 37
    Arora N, Scognamiglio T, Lubitz CC et al. Identification of borderline thyroid tumors by gene expression array analysis. Cancer 2009; 115: 542131.
  • 38
    Rhoden KJ, Unger K, Salvatore G et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 2006; 91: 241423.
  • 39
    Baloch ZW, LiVolsi VA. Encapsulated follicular variant of papillary thyroid carcinoma with bone metastases. Mod Pathol 2000; 13: 8615.